S&P 500   4,080.11 (+3.09%)
DOW   34,589.77 (+2.18%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.24%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)
S&P 500   4,080.11 (+3.09%)
DOW   34,589.77 (+2.18%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.24%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)
S&P 500   4,080.11 (+3.09%)
DOW   34,589.77 (+2.18%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.24%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)
S&P 500   4,080.11 (+3.09%)
DOW   34,589.77 (+2.18%)
QQQ   293.36 (+4.56%)
AAPL   148.03 (+4.86%)
MSFT   255.14 (+6.16%)
META   118.10 (+7.89%)
GOOGL   100.99 (+6.09%)
AMZN   96.54 (+4.46%)
TSLA   194.70 (+7.67%)
NVDA   169.23 (+8.24%)
NIO   12.78 (+21.71%)
BABA   87.56 (+9.64%)
AMD   77.63 (+5.78%)
T   19.28 (+1.42%)
MU   57.65 (+4.59%)
CGC   3.62 (+5.85%)
F   13.90 (+1.09%)
GE   85.97 (+0.36%)
DIS   97.87 (+3.36%)
AMC   7.23 (-2.69%)
PYPL   78.41 (+0.99%)
PFE   50.13 (+1.29%)
NFLX   305.53 (+8.75%)
OTCMKTS:IPSEY

Ipsen - IPSEY Stock Forecast, Price & News

$28.16
+0.16 (+0.57%)
(As of 11/30/2022 12:00 AM ET)
Add
Compare
Today's Range
$27.84
▼
$28.16
50-Day Range
$21.35
▼
$28.30
52-Week Range
$21.17
▼
$32.51
Volume
7,223 shs
Average Volume
1,404 shs
Market Capitalization
$9.44 billion
P/E Ratio
N/A
Dividend Yield
0.86%
Price Target
$107.22

Ipsen MarketRank™ Forecast

Analyst Rating
Hold
1.91 Rating Score
Upside/​Downside
280.8% Upside
$107.22 Price Target
Short Interest
Healthy
0.00% of Shares Sold Short
Dividend Strength
Weak
Based on Four Factors
Sustainability
N/A
News Sentiment
-0.14mentions of Ipsen in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.61 out of 5 stars

See Top Rated MarketRank™ Stocks Here
IPSEY stock logo

About Ipsen (OTCMKTS:IPSEY) Stock

Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, gastroenterology, cognitive disorders, and rare diseases. It offers Somatuline for neuroendocrine tumors and acromegaly; Decapeptyl for the treatment of advanced metastatic prostate cancer; Cabometyx for renal cell and second-line hepatocellular carcinoma; Onivyde for second-line metastatic pancreatic cancer; Dysport for motor muscular disorders and medical aesthetics; NutropinAq for growth failure in children due to growth hormone (GH) deficiency, turner syndrome, chronic renal failure, and GH deficiency in adults; and Increlex for growth failure in children and adolescents. The company also offers Smecta for chronic and acute diarrhea, and pain associated with functional bowel diseases; Forlax for constipation; Fortrans/Eziclen for bowel cleansing prior to endoscopy, X-ray examination, and colonic surgery; and Tanakan for cognitive disorders in adults, vertigo of vestibular origin and vestibular rehabilitation, and tinnitus. In addition, it provides Xermelo for the carcinoid syndrome; Cometriq for medullary thyroid cancer; Smebiocta/SmectaFlora Protect, a food supplement; SmectaGas, a medical device used in the symptomatic treatment of gas-related gastrointestinal disorders and relief of gas-related symptoms; and Etiasa for inflammatory bowel diseases. Further, the company offers other consumer healthcare products in the gastro-intestinal area, including Buscopan, Clin4000, Prontalgine, Suppositoria Glycerini, Mucothiol, Floractin, and Mucodyne. Ipsen S.A. has agreements with Debiopharm; Exelixis; Galderma; Blueprint Medicines; TerSera Therapeutics; Rhythm Pharmaceuticals; Teijin; Braintree Laboratories; Ethypharm; Schwabe; BAKX Therapeutics Inc.; and Exicure. The company was founded in 1929 and is headquartered in Boulogne-Billancourt, France.

Receive IPSEY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter.

IPSEY Stock News Headlines

November 29, 2022 | americanbankingnews.com
Ipsen S.A. (OTCMKTS:IPSEY) Receives Consensus Recommendation of "Hold" from Analysts
November 9, 2022 | seekingalpha.com
Merrimack jumps 183% as partner Ipsen says pancreatic cancer trial met main goal
November 9, 2022 | seekingalpha.com
Ipsen Onivyde combo meets trial's survival goal in untreated pancreatic cancer patients
October 27, 2022 | finance.yahoo.com
Ipsen Delivers Strong Sales Growth in the First Nine Months of 2022 and Confirms Its Full-year Guidance
October 25, 2022 | markets.businessinsider.com
Ipsen : FDA Postpones Palovarotene Advisory Committee Meeting
September 24, 2022 | msn.com
Ipsen set to invest extra €15m in Dublin
September 6, 2022 | apnews.com
IRLAB’s partner Ipsen Initiates Clinical Studies in Line with Mesdopetam’s Development Plan
August 12, 2022 | finance.yahoo.com
Ipsen Completes Acquisition of Epizyme Expanding Its Portfolio in Oncology
August 5, 2022 | finance.yahoo.com
Ipsen Extends Expiration Date of Tender Offer for Epizyme, Inc. to 11 August 2022
August 3, 2022 | finance.yahoo.com
Merrimack Pharma-Ipsen's Cancer Drug Fails In Overall Survival Measure
August 3, 2022 | markets.businessinsider.com
Ipsen: Phase III RESILIENT Trial Evaluating Onivyde Fails To Meet Primary Endpoint
August 3, 2022 | seekingalpha.com
Ipsen Onivyde fails to improve overall survival of lung cancer patients in phase 3 trial
August 1, 2022 | nasdaq.com
Ipsen To Advance Immuno-Oncology Candidates From Marengo's STAR Platform Into Clinic
July 30, 2022 | seekingalpha.com
Ipsen S.A. 2022 Q2 - Results - Earnings Call Presentation
July 30, 2022 | seekingalpha.com
Ipsen S.A.'s (IPSEY) CEO David Loew on Q2 2022 Results - Earnings Call Transcript
July 28, 2022 | marketwatch.com
Ipsen Shares Rise on 1H Results, Higher 2022 View
July 28, 2022 | finance.yahoo.com
Ipsen Delivers Strong H1 2022 Results and Upgrades Its Full-Year Guidance
June 29, 2022 | finance.yahoo.com
Biotech Stock Roundup: EPZM Soars on IPSEY Offer, KZR Up on Study Data & More
June 29, 2022 | seekingalpha.com
Ipsen's rare bone/tissue disorder drug gets FDA priority review
June 29, 2022 | nasdaq.com
Ipsen Announces FDA Priority Review For Palovarotene NDA In Patients With Rare Genetic Disorder
June 29, 2022 | finance.yahoo.com
Ipsen Announces U.S. FDA Priority Review for palovarotene New Drug Application in Patients With Fibrodysplasia Ossificans Progressiva Following Resubmission
June 27, 2022 | nasdaq.com
Epizyme (EPZM) Stock Surges on Acquisition Offer From Ipsen
June 27, 2022 | finance.yahoo.com
Ipsen Scoops Up Blood Cancer-Focused Epizyme - Read Why
June 27, 2022 | finance.yahoo.com
Why Epizyme Stock Is Soaring Today
June 27, 2022 | seekingalpha.com
Epizyme stock soars 60% as Ipsen set to acquire the cancer drugmaker
See More Headlines
Receive IPSEY Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Ipsen and its competitors with MarketBeat's FREE daily newsletter.

IPSEY Company Calendar

Today
11/30/2022
Fiscal Year End
12/31/2022
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
OTCMKTS
Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
OTCMKTS:IPSEY
CUSIP
N/A
CIK
N/A
Web
www.ipsen.com
Phone
(315) 833-5000
Fax
33-01-58-33-50-01
Employees
5,700
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$107.22
High Stock Price Forecast
$142.00
Low Stock Price Forecast
$86.00
Forecasted Upside/Downside
+280.8%
Consensus Rating
Hold
Rating Score (0-4)
1.91
Research Coverage
11 Analysts

Profitability

EPS (Most Recent Fiscal Year)
N/A
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
N/A
Quick Ratio
N/A

Sales & Book Value

Annual Sales
$3.55 billion
Price / Sales
2.66
Cash Flow
$3.49 per share
Price / Cash Flow
8.06
Book Value
$9.72 per share
Price / Book
2.90

Miscellaneous

Outstanding Shares
335,260,000
Free Float
N/A
Market Cap
$9.44 billion
Optionable
Not Optionable
Beta
1.02

Key Executives

  • Mr. David Loew (Age 55)
    MD, CEO & Director
    Comp: $2.26M
  • Mr. Aymeric Le Chatelier (Age 53)
    Exec. VP & Group CFO
  • Dr. Aidan Murphy Ph.D. (Age 56)
    Exec. VP of Technical Operations
  • Mr. Craig Marks
    Vice-Pres of Investor Relations
  • Mr. Francois Garnier (Age 60)
    Exec. VP of Legal Affairs, Gen. Counsel & Chief Bus. Ethics Officer
  • Ms. Gwenan White
    Exec. VP of Communications & Public Affairs
  • Mr. Regis Mulot (Age 56)
    Exec. VP & Chief HR Officer
  • Mr. Stephan Gagne
    Head of New Tokyo Office
  • Ms. Dominique Bery (Age 51)
    Head of Nordics & Baltics
  • Dr. Yan Moore M.D. (Age 55)
    Sr. VP & Head of Oncology Therapeutic Area

Key Competitors

View All Competitors













IPSEY Stock - Frequently Asked Questions

Should I buy or sell Ipsen stock right now?

11 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Ipsen in the last twelve months. There are currently 3 sell ratings, 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" IPSEY shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in IPSEY, but not buy additional shares or sell existing shares.
View IPSEY analyst ratings or view top-rated stocks.

What is Ipsen's stock price forecast for 2023?

11 brokerages have issued 12-month price objectives for Ipsen's stock. Their IPSEY share price forecasts range from $86.00 to $142.00. On average, they predict the company's share price to reach $107.22 in the next year. This suggests a possible upside of 282.9% from the stock's current price.
View analysts price targets for IPSEY or view top-rated stocks among Wall Street analysts.

How have IPSEY shares performed in 2022?

Ipsen's stock was trading at $23.47 on January 1st, 2022. Since then, IPSEY stock has increased by 19.3% and is now trading at $28.00.
View the best growth stocks for 2022 here.

Are investors shorting Ipsen?

Ipsen saw a increase in short interest in November. As of November 15th, there was short interest totaling 2,600 shares, an increase of 188.9% from the October 31st total of 900 shares. Based on an average trading volume of 2,000 shares, the days-to-cover ratio is currently 1.3 days.
View Ipsen's Short Interest.

How often does Ipsen pay dividends? What is the dividend yield for Ipsen?

Ipsen declared a dividend on Friday, May 27th. Shareholders of record on Wednesday, June 1st will be paid a dividend of $0.2269 per share on Thursday, June 9th. This represents a yield of 0.88%. The ex-dividend date is Tuesday, May 31st.
Read our dividend analysis for IPSEY.

Is Ipsen a good dividend stock?

Ipsen (OTCMKTS:IPSEY) pays an annual dividend of $0.24 per share and currently has a dividend yield of 0.84%.
Read our dividend analysis for IPSEY.

What is Ipsen's stock symbol?

Ipsen trades on the OTCMKTS under the ticker symbol "IPSEY."

How do I buy shares of Ipsen?

Shares of IPSEY stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Ipsen's stock price today?

One share of IPSEY stock can currently be purchased for approximately $28.00.

How many employees does Ipsen have?

The company employs 5,700 workers across the globe.

How can I contact Ipsen?

Ipsen's mailing address is 65 quai Georges Gorse, Boulogne-Billancourt cedex I0, 92650. The official website for the company is www.ipsen.com. The company can be reached via phone at (315) 833-5000, via email at investor.relations@ipsen.com, or via fax at 33-01-58-33-50-01.

This page (OTCMKTS:IPSEY) was last updated on 11/30/2022 by MarketBeat.com Staff